Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HB0025 + pemetrexed + carboplatin
- Development stage
- Phase 3
- Lead developer
- Shanghai Huaota Biopharmaceutical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
HB0025 + pemetrexed + carboplatin is an investigational combination regimen being studied primarily in advanced non-squamous non-small cell lung cancer (NSCLC). HB0025 is a recombinant fusion protein targeting the programmed cell death protein 1 (PD-1) immune checkpoint, acting as an immunotherapeutic agent. Pemetrexed is an antifolate chemotherapy agent that targets folate-dependent enzymes, interfering with DNA and RNA synthesis, and carboplatin is a platinum-based chemotherapeutic that forms DNA crosslinks, leading to apoptosis. This combination is designed to maximize cancer cell killing through both immune modulation (via HB0025) and cytotoxic approaches (via pemetrexed and carboplatin). The regimen is being evaluated for safety, tolerability, and efficacy in Phase Ib/II clinical trials for patients with recurrent, metastatic, or locally advanced non-squamous NSCLC who have not received prior systemic therapy and do not carry EGFR sensitive mutations or ALK fusion gene sensitive mutations[3].
- Other names
- HB0025HB-0025HB 0025pemetrexedcarboplatin
02
Targets
DNADHFR (Dihydrofolate reductase)GART (GAR transformylase)CD274 (Programmed cell death protein 1 ligand 1)TS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on HB0025 + pemetrexed + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HB0025 + pemetrexed + carboplatin.